PTGS2 and colorectal carcinoma: In a landmark study, Keisuke Kosumi, et al. employed Cox proportional hazards regression to analyze data from 1,708 stage I–IV CRC patients, revealing a statistically significant interaction between COX-2 expression and BRAF mutation status.